| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5441958 | NOVARTIS | Ophthalmic compositions comprising emedastine and methods for their use |
Dec, 2013
(10 years ago) | |
Emadine is owned by Novartis.
Emadine contains Emedastine Difumarate.
Emadine has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Emadine are:
- US5441958
Emadine was authorised for market use on 29 December, 1997.
Emadine is available in solution/drops;ophthalmic dosage forms.
Emadine can be used as treatment of allergic conjunctivitis.
The generics of Emadine are possible to be released after 08 December, 2013.
Drugs and Companies using EMEDASTINE DIFUMARATE ingredient
Market Authorisation Date: 29 December, 1997
Treatment: Treatment of allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
More Information on Dosage
EMADINE family patents
